🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just published! Results of this study from researchers in Spain suggest that IGHV subset 2 may improve risk score assessment accuracy in patients with chronic lymphocytic leukemia. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert #leusm

CD19-directed chimeric antigen receptor T-cells provide a novel therapeutic avenue for recurrent neurolymphomatosis, a distinct NHL subtype with unmet medical need doi.org/10.1002/ajh.27… #CART #hemonc

Lleno absoluto en el simposio de linfomas agresivos 🗣️ Ana Marín Niebla explica cómo la llegada de los BTKis en primera línea cambiará la práctica. “The erlier use of ibrutinib in R/R, the better” #Hemato2024

Esta maña el Dr. Carlos Fernandez de Larrea nos ha explicado el tratamiento con anticuerpos biespecificos en el #Mieloma múltiple de una manera muy didáctica y entretenida, hablando también de secuenciación con CAR-T #mmsm #Hemato2024 Hospital Clínic @sehh_es

Inicia el segundo día de VI Curso de Aspectos Prácticos de la Terapia CAR-T Julio Delgado Nil Albiol Alvaro Urbano-Ispizua Hematologia Hospital Clínic Barcelona

San Diego, here we go! #ASH2024 Nil Albiol

Happy to share our comprehensive study on non-hematologic autoinmune disorders in CLL patients at #ASH24 Expansion of IL-17-F producing cells mediated by IL23 may explain lower risk of leukemic progression. Come to discuss our results at 5:30pm 🙂

European Hematology Association You will not find a more interesting and exciting experience in #clinicalresearch training in #hematology. European Hematology Association #CRTH is the best educational program for early stage career hematologists. Stay tuned for the next call in June 2025!!

Academic CART cell Myeloma #ARI0002h #CART25 Carlos Fernandez de Larrea Hematologia Hospital Clínic Barcelona The EBMT Hospital Clínic

CONGRESS | #CART25 | PRESENTATION Carlos Fernández de Larrea Carlos Fernandez de Larrea Hospital Clínic highlights results from a study of ARI0002h in patients with R/R multiple myeloma, and discusses the potential impact of academic point-of-care CAR T-cell manufacturing on access to CAR

Nil Albiol (Hematologia Hospital Clínic Barcelona) es el único hematólogo español que está participando en esta edición de European Hematology Association #CRTH. Excelente trabajo y gran progreso a lo largo del workshop 1. ¡Felicidades! Deseando ver progresos en la reunión de #EHA2025. @sehh_es SEHH Joven

I’m very happy to be part of the #CRTH European Hematology Association The first workshop at Milan has been wonderful so far, with great faculty team that have helped me a lot to improve my project. Also met some great people there, we had a great time together! See you at #EHA2025

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma ashpublications.org/blood/article-…

Congrats to everyone! Especially to Sirpa Leppa and Julio Delgado Hematologia Hospital Clínic Barcelona

Happy to present two posters about molecular MRD in AML at #EHA2025 in Milan. Check them out at today’s poster session!

Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and hematologic improvement. Learn more: nej.md/3SM6S4V

CONGRESS | #EHA2025 | POSTER Juan Du, Shanghai Changzheng Hospital, presents updated phase I results on 1L BCMA-CD19 dual CAR-T therapy in transplant-eligible high-risk NDMM (N=22). Median FU=37.1 months. High response rates: ORR and MRD-neg=100%; sCR=95%. Median DoR not reached.